| Mo | CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of Hematology Meeting | PR Newswire |
| 06.11.19 | CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting | PR Newswire |
| 04.11.19 | CTI BioPharma Reports Third Quarter 2019 Financial Results | PR Newswire |
| 01.10.19 | CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia | PR Newswire |
| |
| 01.08.19 | CTI BioPharma Reports Second Quarter 2019 Financial Results | PR Newswire |
| 18.07.19 | CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis | PR Newswire |
| 13.06.19 | CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20 | PR Newswire |
| 29.05.19 | CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5 | PR Newswire |
| 02.05.19 | CTI BioPharma Reports First Quarter 2019 Financial Results | PR Newswire |
| |
| 03.04.19 | CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10 | PR Newswire |
| 13.03.19 | CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights | PR Newswire |
| 12.03.19 | CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19 | PR Newswire |
| 20.02.19 | CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27 | PR Newswire |
| 11.02.19 | CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX® | PR Newswire |
| 01.02.19 | CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update | PR Newswire |
| 28.12.18 | CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib | PR Newswire |
| 18.12.18 | CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development | PR Newswire |
| 13.12.18 | CTI BioPharma Announces Restructuring Plan | PR Newswire |
| 26.11.18 | CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency | PR Newswire |
| 01.11.18 | CTI BioPharma Reports Third Quarter 2018 Financial Results | PR Newswire |
| 25.10.18 | CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018 | PR Newswire |
| 01.10.18 | CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review | PR Newswire |
| 26.09.18 | CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3 | PR Newswire |
| 02.08.18 | CTI BioPharma Reports Second Quarter 2018 Financial Results | PR Newswire |
| 26.07.18 | CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018 | PR Newswire |
| 18.07.18 | CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA | PR Newswire |
| 09.07.18 | Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma | PR Newswire |
| 02.07.18 | CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib | PR Newswire |
| 14.06.18 | CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference | PR Newswire |
| 06.06.18 | CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference | PR Newswire |
| 03.05.18 | CTI BioPharma Reports First Quarter 2018 Financial Results | PR Newswire |
| 26.04.18 | CTI BioPharma to Report First Quarter 2018 Financial Results on May 3, 2018 | PR Newswire |
| 09.03.18 | CTI BioPharma to Present at Upcoming Investor Conferences | PR Newswire |
| 09.03.18 | CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology | PR Newswire |
| 07.03.18 | CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results | PR Newswire |
| 28.02.18 | CTI BioPharma to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018 | PR Newswire |
| 14.02.18 | CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference | PR Newswire |
| 13.02.18 | CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock | PR Newswire |
| 09.02.18 | CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock | PR Newswire |
| 05.02.18 | CTI BioPharma Announces Launch of Follow-On Offering | PR Newswire |
| 25.01.18 | CTI BioPharma Provides Corporate and European Regulatory Update | PR Newswire |
| 18.01.18 | CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX® | PR Newswire |
| 08.11.17 | CTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference | PR Newswire |
| 06.11.17 | CTI BioPharma Reports Third Quarter 2017 Financial Results | PR Newswire |
| 30.10.17 | CTI BioPharma to Report Third Quarter 2017 Financial Results on November 6, 2017 | PR Newswire |
| 26.09.17 | CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions | PR Newswire |
| 31.08.17 | CTI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference | PR Newswire |
| 03.08.17 | CTI BioPharma Reports Second Quarter 2017 Financial Results | PR Newswire |
| 02.08.17 | CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma | PR Newswire |
| 01.08.17 | CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib | PR Newswire |
Zum Seitenanfang
